Novel mutations in the RFXANK gene

RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II

Wojciech Wiszniewski, Marie Claude Fondaneche, Pascale Louise-Plence, Ada Prochnicka-Chalufour, Françoise Selz, Cappucine Picard, Françoise Deist, Jean François Eliaou, Alain Fischer, Barbara Lisowska-Grospierre

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

MHC class II deficiency is a combined immunodeficiency caused by defects in the four regulatory factors, CIITA, RFXANK, RFX5 and RFXAP, that control MHC II expression at the transcriptional level. The RFXANK gene encodes one subunit of the heterotrimeric RFX complex that is involved in the assembly of several transcription factors on MHC II promoters. Seven different RFXANK mutations have previously been reported in 26 unrelated patients. The most frequent mutation, a 26-bp deletion (752delG-25), has been identified in 21 patients. The other mutations are all nonsense or splice-site mutations, leading to proteins lacking all or part of the RFXANK ankyrin repeat region. We report two novel missense mutations, D121V and R212X, resulting in loss of function of the gene. We investigated the in vivo effects of these mutations and of three other point mutations on the expression of the RFXANK RNA and protein. The number of RFXANK transcripts was severely reduced in all patients except one. The RFXANK protein was barely detected in two cases. In addition, guided by a structural model of RFXANK, we investigated experimental mutants of the C-terminal tyrosine 224. Substitution Y224A, but not Y224F, led to the loss of function of RFXANK. Two null mutants, D121V and Y224A, were tested in protein interaction and DNA binding assays. The D121V mutant was unable to form the RFX complex, indicating that D121 is required for RFXAP binding. The Y224A mutant formed an RFX complex that bound normally to the MHC II promoter, but did not lead to MHC class II expression, whereas Y224F RFXANK retained the wild-type function. This indicates that an aromatic ring, but not the phenyl chain of tyrosine, is necessary at position 224 for normal RFXANK function. Studies on the Y224A mutant suggest that, in addition to the RFX subunits and CIITA, another protein is essential for MHC class II expression. This protein appears to interact with the fourth ankyrin repeat of RFXANK.

Original languageEnglish (US)
Pages (from-to)747-755
Number of pages9
JournalImmunogenetics
Volume54
Issue number11
StatePublished - Feb 1 2003
Externally publishedYes

Fingerprint

Mutation
Ankyrin Repeat
Genes
Proteins
Tyrosine
Nonsense Codon
Structural Models
DNA-Binding Proteins
Missense Mutation
Point Mutation
Transcription Factors
In Vitro Techniques
RNA

Keywords

  • Ankyrin repeat
  • MHC II
  • RFXANK
  • Transcription

ASJC Scopus subject areas

  • Immunology
  • Genetics

Cite this

Wiszniewski, W., Fondaneche, M. C., Louise-Plence, P., Prochnicka-Chalufour, A., Selz, F., Picard, C., ... Lisowska-Grospierre, B. (2003). Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II. Immunogenetics, 54(11), 747-755.

Novel mutations in the RFXANK gene : RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II. / Wiszniewski, Wojciech; Fondaneche, Marie Claude; Louise-Plence, Pascale; Prochnicka-Chalufour, Ada; Selz, Françoise; Picard, Cappucine; Deist, Françoise; Eliaou, Jean François; Fischer, Alain; Lisowska-Grospierre, Barbara.

In: Immunogenetics, Vol. 54, No. 11, 01.02.2003, p. 747-755.

Research output: Contribution to journalArticle

Wiszniewski, W, Fondaneche, MC, Louise-Plence, P, Prochnicka-Chalufour, A, Selz, F, Picard, C, Deist, F, Eliaou, JF, Fischer, A & Lisowska-Grospierre, B 2003, 'Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II', Immunogenetics, vol. 54, no. 11, pp. 747-755.
Wiszniewski W, Fondaneche MC, Louise-Plence P, Prochnicka-Chalufour A, Selz F, Picard C et al. Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II. Immunogenetics. 2003 Feb 1;54(11):747-755.
Wiszniewski, Wojciech ; Fondaneche, Marie Claude ; Louise-Plence, Pascale ; Prochnicka-Chalufour, Ada ; Selz, Françoise ; Picard, Cappucine ; Deist, Françoise ; Eliaou, Jean François ; Fischer, Alain ; Lisowska-Grospierre, Barbara. / Novel mutations in the RFXANK gene : RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II. In: Immunogenetics. 2003 ; Vol. 54, No. 11. pp. 747-755.
@article{aee6082902bf4eadb81cf4936ff55d29,
title = "Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II",
abstract = "MHC class II deficiency is a combined immunodeficiency caused by defects in the four regulatory factors, CIITA, RFXANK, RFX5 and RFXAP, that control MHC II expression at the transcriptional level. The RFXANK gene encodes one subunit of the heterotrimeric RFX complex that is involved in the assembly of several transcription factors on MHC II promoters. Seven different RFXANK mutations have previously been reported in 26 unrelated patients. The most frequent mutation, a 26-bp deletion (752delG-25), has been identified in 21 patients. The other mutations are all nonsense or splice-site mutations, leading to proteins lacking all or part of the RFXANK ankyrin repeat region. We report two novel missense mutations, D121V and R212X, resulting in loss of function of the gene. We investigated the in vivo effects of these mutations and of three other point mutations on the expression of the RFXANK RNA and protein. The number of RFXANK transcripts was severely reduced in all patients except one. The RFXANK protein was barely detected in two cases. In addition, guided by a structural model of RFXANK, we investigated experimental mutants of the C-terminal tyrosine 224. Substitution Y224A, but not Y224F, led to the loss of function of RFXANK. Two null mutants, D121V and Y224A, were tested in protein interaction and DNA binding assays. The D121V mutant was unable to form the RFX complex, indicating that D121 is required for RFXAP binding. The Y224A mutant formed an RFX complex that bound normally to the MHC II promoter, but did not lead to MHC class II expression, whereas Y224F RFXANK retained the wild-type function. This indicates that an aromatic ring, but not the phenyl chain of tyrosine, is necessary at position 224 for normal RFXANK function. Studies on the Y224A mutant suggest that, in addition to the RFX subunits and CIITA, another protein is essential for MHC class II expression. This protein appears to interact with the fourth ankyrin repeat of RFXANK.",
keywords = "Ankyrin repeat, MHC II, RFXANK, Transcription",
author = "Wojciech Wiszniewski and Fondaneche, {Marie Claude} and Pascale Louise-Plence and Ada Prochnicka-Chalufour and Fran{\cc}oise Selz and Cappucine Picard and Fran{\cc}oise Deist and Eliaou, {Jean Fran{\cc}ois} and Alain Fischer and Barbara Lisowska-Grospierre",
year = "2003",
month = "2",
day = "1",
language = "English (US)",
volume = "54",
pages = "747--755",
journal = "Immunogenetics",
issn = "0093-7711",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Novel mutations in the RFXANK gene

T2 - RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II

AU - Wiszniewski, Wojciech

AU - Fondaneche, Marie Claude

AU - Louise-Plence, Pascale

AU - Prochnicka-Chalufour, Ada

AU - Selz, Françoise

AU - Picard, Cappucine

AU - Deist, Françoise

AU - Eliaou, Jean François

AU - Fischer, Alain

AU - Lisowska-Grospierre, Barbara

PY - 2003/2/1

Y1 - 2003/2/1

N2 - MHC class II deficiency is a combined immunodeficiency caused by defects in the four regulatory factors, CIITA, RFXANK, RFX5 and RFXAP, that control MHC II expression at the transcriptional level. The RFXANK gene encodes one subunit of the heterotrimeric RFX complex that is involved in the assembly of several transcription factors on MHC II promoters. Seven different RFXANK mutations have previously been reported in 26 unrelated patients. The most frequent mutation, a 26-bp deletion (752delG-25), has been identified in 21 patients. The other mutations are all nonsense or splice-site mutations, leading to proteins lacking all or part of the RFXANK ankyrin repeat region. We report two novel missense mutations, D121V and R212X, resulting in loss of function of the gene. We investigated the in vivo effects of these mutations and of three other point mutations on the expression of the RFXANK RNA and protein. The number of RFXANK transcripts was severely reduced in all patients except one. The RFXANK protein was barely detected in two cases. In addition, guided by a structural model of RFXANK, we investigated experimental mutants of the C-terminal tyrosine 224. Substitution Y224A, but not Y224F, led to the loss of function of RFXANK. Two null mutants, D121V and Y224A, were tested in protein interaction and DNA binding assays. The D121V mutant was unable to form the RFX complex, indicating that D121 is required for RFXAP binding. The Y224A mutant formed an RFX complex that bound normally to the MHC II promoter, but did not lead to MHC class II expression, whereas Y224F RFXANK retained the wild-type function. This indicates that an aromatic ring, but not the phenyl chain of tyrosine, is necessary at position 224 for normal RFXANK function. Studies on the Y224A mutant suggest that, in addition to the RFX subunits and CIITA, another protein is essential for MHC class II expression. This protein appears to interact with the fourth ankyrin repeat of RFXANK.

AB - MHC class II deficiency is a combined immunodeficiency caused by defects in the four regulatory factors, CIITA, RFXANK, RFX5 and RFXAP, that control MHC II expression at the transcriptional level. The RFXANK gene encodes one subunit of the heterotrimeric RFX complex that is involved in the assembly of several transcription factors on MHC II promoters. Seven different RFXANK mutations have previously been reported in 26 unrelated patients. The most frequent mutation, a 26-bp deletion (752delG-25), has been identified in 21 patients. The other mutations are all nonsense or splice-site mutations, leading to proteins lacking all or part of the RFXANK ankyrin repeat region. We report two novel missense mutations, D121V and R212X, resulting in loss of function of the gene. We investigated the in vivo effects of these mutations and of three other point mutations on the expression of the RFXANK RNA and protein. The number of RFXANK transcripts was severely reduced in all patients except one. The RFXANK protein was barely detected in two cases. In addition, guided by a structural model of RFXANK, we investigated experimental mutants of the C-terminal tyrosine 224. Substitution Y224A, but not Y224F, led to the loss of function of RFXANK. Two null mutants, D121V and Y224A, were tested in protein interaction and DNA binding assays. The D121V mutant was unable to form the RFX complex, indicating that D121 is required for RFXAP binding. The Y224A mutant formed an RFX complex that bound normally to the MHC II promoter, but did not lead to MHC class II expression, whereas Y224F RFXANK retained the wild-type function. This indicates that an aromatic ring, but not the phenyl chain of tyrosine, is necessary at position 224 for normal RFXANK function. Studies on the Y224A mutant suggest that, in addition to the RFX subunits and CIITA, another protein is essential for MHC class II expression. This protein appears to interact with the fourth ankyrin repeat of RFXANK.

KW - Ankyrin repeat

KW - MHC II

KW - RFXANK

KW - Transcription

UR - http://www.scopus.com/inward/record.url?scp=0037304181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037304181&partnerID=8YFLogxK

M3 - Article

VL - 54

SP - 747

EP - 755

JO - Immunogenetics

JF - Immunogenetics

SN - 0093-7711

IS - 11

ER -